AstraZeneca Investor Conference Presentation Deck
Baxdrostat: addresses a large unmet need in cardiorenal disease
A potential best-in-class ASI for treatment resistant hypertension
Baxdrostat (CIN-107) – a highly selective,
aldosterone synthase inhibitor (ASI)
Baxdrostat is highly selective for aldosterone synthase and spares
the cortisol pathway
BrigHTN Phase II trial:
Baxdrostat significantly reduced systolic BP after 12-week
treatment period, in treatment-resistant hypertensive patients
(on diuretics, CCBS, BBs, ACES or ARBs)
C Change in Systolic Blood Pressure over Time
-Placebo - Baxdrostat, →→ Baxdrostat,
0.5 mg
1 mg
LSM Change
(mm Hg)
0-
-5-
-10-
-15-
-20-
-25-
-30+
0
20
40
T
60
→Baxdrostat,
2 mg
80
100
Trial Day
Well tolerated in Phase II trials, does not generate the same level
of androgenic AEs as MRAs used for trHTN
Hypertension: high-risk factor for stroke, CAD, heart
attack and CKD; current treatment options limited
Baxdrostat is a potential leading next-generation
ASI: expected to help control blood pressure in patients
with tough to control hypertension. Phase III to start H1
2023
Strong strategic fit to build leading cardiorenal portfolio:
potential for combinations with Farxiga, aiming to
provide both BP reduction and organ protection
Deal terms
$26 per share in cash at deal closing
(upfront equity value of $1.3bn)
- At transaction close, AstraZeneca will acquire CinCor's
cash and marketable securities (~$0.5bn)
A non-tradable contingent value right of $10 per share in
cash payable upon a specified regulatory submission of
baxdrostat
10 CCB = calcium channel blockers; BBs = beta blockers; ACE = angiotensin-converting enzyme; AE = adverse events; ARBS = angiotensin receptor blockers; ASI = aldosterone synthase inhibitors; MRAS = mineralocorticoid receptor
antagonists; CAD = coronary arterial disease; CKD = chronic kidney disease; BP = blood pressure; trHTN = treatment-resistant hypertension.View entire presentation